Tumor-suppressing effect of bartogenic acid in ovarian (SKOV-3) xenograft mouse model
- 13 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 394 (8), 1815-1826
- https://doi.org/10.1007/s00210-021-02088-0
Abstract
Bartogenic acid (BA), a natural pentacyclic triterpenoid, proved to have chemomodulatory, anticancer, antidiabetic, anti-arthritic, and anti-inflammatory activity. Based on structure–activity relationship (SAR) approaches, BA has close structural resemblance to oleanolic acid and ursolic acid. These two pentacyclic triterpenoids are well accepted with respect to their therapeutic value in various ailments including anti-cancer activity. The aim of this study is to evaluate the efficacy of BA as a possible antitumor agent, along with its safety in SKOV-3 ovarian cancer. In vitro cytotoxicity of BA and paclitaxel on human ovarian cancer cells (SKOV-3) was assessed using MTT assay. Antitumor potential of BA alone, standard anticancer drug (paclitaxel) alone, and BA in combination with paclitaxel were evaluated in SKOV-3 xenografted SCID mice. Immunohistochemical analysis of NF-κB was performed and analyzed in SKOV-3 tumors. BA alone and BA in combination with paclitaxel significantly inhibited the tumor growth. IC50 of BA was found to be 15.72 μM. Similarly, paclitaxel showed significant antitumor effect with IC50 of 3.234 μM. Treatments of paclitaxel, BA, and combination of BA with paclitaxel were well tolerated during treatment period. Immunohistochemical analysis of NF-κB in SKOV-3 tumors treated with BA in combination with paclitaxel revealed antitumor effect in terms of inhibition of NF-κB. Our results suggested that BA exhibits promising antitumor effect in the restriction of SKOV-3 cells and tumors with considerable safety.Keywords
This publication has 49 references indexed in Scilit:
- Triterpenoids as reversal agents for anticancer drug resistance treatmentDrug Discovery Today, 2014
- Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in TaiwanJournal of Gynecologic Oncology, 2013
- Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancerCancer Letters, 2012
- Antidiabetic Activity ofGnidia glaucaandDioscorea bulbifera: Potent Amylase and Glucosidase InhibitorsEvidence-Based Complementary and Alternative Medicine, 2011
- Anti-Arthritic Activity of Bartogenic Acid Isolated from Fruits ofBarringtonia racemosaRoxb. (Lecythidaceae)Evidence-Based Complementary and Alternative Medicine, 2011
- Triterpenoids as potential agents for the chemoprevention and therapy of breast cancerFrontiers in Bioscience-Landmark, 2011
- Targeting Inflammatory Pathways by Triterpenoids for Prevention and Treatment of CancerToxins, 2010
- Cytotoxic Pentacyclic Triterpenoids from Combretum sundaicum and Lantana camara as Inhibitors of Bcl-xL/BakBH3 Domain Peptide InteractionJournal of Natural Products, 2009
- Pentacyclic Triterpene Distribution in Various Plants – Rich Sources for a New Group of Multi-Potent Plant ExtractsMolecules, 2009
- Oleanane-Type Isomeric Triterpenoids from Barringtonia racemosaJournal of Natural Products, 2009